Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with Merck & Co’s anti-PD-1 therapy ...

Gilead Sciences announced significant results from a Phase 3 study of Trodelvy combined with Merck's Keytruda in treating ...

The Phase 3 trial compared the Trodelvy-Keytruda combo to a standard initial treatment of chemotherapy and Keytruda in 443 previously untreated patients with advanced triple-negative breast cancer ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...